MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans

MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans

Strategies to enhance the induction of high magnitude T cell responses through vaccination are urgently needed. Major histocompatibility complex (MHC) class II–associated invariant chain (Ii) plays a critical role in antigen presentation, forming MHC class II peptide complexes for the generation of...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Esposito, I, Cicconi, P, D'Alise, AM, Brown, A, Esposito, M, Swadling, L, Holst, PJ, Bassi, MR, Stornaiuolo, M, Mori, F, Vassilev, V, Li, W, Donnison, T, Gentile, C, Turner, B, von Delft, A, Del Sorbo, M, Barra, F, Contino, AM, Abbate, A, Novellino, E, Thomsen, AR, Christensen, JP, Lahm, A, Grazioli, F, Ammendola, V, Siani, L, Colloca, S, Klenerman, P, Nicosia, A, Dorrell, L, Folgori, A, Capone, S, Barnes, E
Altri autori:	PEACHI Consortium
Natura:	Journal article
Lingua:	English
Pubblicazione:	American Association for the Advancement of Science 2020

Documenti analoghi

Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans
di: Kelly, C, et al.
Pubblicazione: (2016)

Chronic Hepatitis C Virus infection subverts vaccine induced T-cell immunity in humans.
di: Kelly, C, et al.
Pubblicazione: (2016)

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory
di: Swadling, L, et al.
Pubblicazione: (2014)

Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates
di: Angiolo Pierantoni, et al.
Pubblicazione: (2015-01-01)

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates
di: Capone, S, et al.
Pubblicazione: (2010)

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates.
di: Capone, S, et al.
Pubblicazione: (2010)

A novel vaccine strategy employing serologically different chimpanzee adenoviral vectors for the prevention of HIV-1 and HCV coinfection
di: Hartnell, F, et al.
Pubblicazione: (2019)

Highly immunogenic virally vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection
di: Swadling, L, et al.
Pubblicazione: (2016)

Highly-immunogenic virally-vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection
di: Swadling, L, et al.
Pubblicazione: (2016)

Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man
di: Barnes, E, et al.
Pubblicazione: (2012)

A highly immunogenic novel genetic vaccine against HCV
di: Del Sorbo, M, et al.
Pubblicazione: (2012)

Hepatitis Hide and Seek
di: Barnes, E, et al.
Pubblicazione: (2012)

Prime and pull of T cell responses against cancer-exogenous antigens is effective against CPI-resistant tumors
di: Fulvia Troise, et al.
Pubblicazione: (2024-03-01)

Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.
di: Colloca, S, et al.
Pubblicazione: (2012)

Correction: A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C.
di: Federico Napolitano, et al.
Pubblicazione: (2021-04-01)

A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection
di: Felicity Hartnell, et al.
Pubblicazione: (2019-01-01)

Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes
di: Donnison, T, et al.
Pubblicazione: (2020)

PHASE I TRIAL OF A HIGHLY IMMUNOGENIC T CELL VACCINE FOR HEPATITIS C VIRUS BASED ON NOVEL ADENOVIRAL VECTORS FROM RARE SEROTYPES
di: Folgori, A, et al.
Pubblicazione: (2009)

A THERAPEUTIC VACCINE FOR HCV BASED ON NOVEL, RARE, ADENOVIRAL VECTORS
di: Kelly, C, et al.
Pubblicazione: (2011)

Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection
di: Leo Swadling, et al.
Pubblicazione: (2016-08-01)

Historical analysis of rainfall-triggered rockfalls: the case study of the disaster of the ancient hydrothermal Sclafani Spa (Madonie Mts, northern-central Sicily, Italy) in 1851
di: A. Contino, et al.
Pubblicazione: (2017-12-01)

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses.
di: Reyes-Sandoval, A, et al.
Pubblicazione: (2010)

Erratum: Prime-boost immunization with adenoviral and modified vaccinia virus ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses
di: Reyes-Sandoval, A, et al.
Pubblicazione: (2011)

Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8(+) T-Cell Responses, (vol 78, pg 152, 2010)
di: Reyes-Sandoval, A, et al.
Pubblicazione: (2011)

Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
di: Green, C, et al.
Pubblicazione: (2015)

Formyl-Peptide Receptor 2 Signaling Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming of Lung Cancer Cells
di: Tiziana Pecchillo Cimmino, et al.
Pubblicazione: (2022-08-01)

Formyl-peptide receptor 2 signalling triggers aerobic metabolism of glucose through Nox2-dependent modulation of pyruvate dehydrogenase activity
di: Tiziana Pecchillo Cimmino, et al.
Pubblicazione: (2023-10-01)

PHASE I TRIAL OF A HIGHLY IMMUNOGENIC AND DURABLE T-CELL VACCINE FOR HEPATITIS C VIRUS BASED ON NOVEL, RARE, ADENOVIRAL VECTORS
di: Barnes, E, et al.
Pubblicazione: (2011)

Pathophysiology of ischaemic heart disease
di: Pocock, MO, et al.
Pubblicazione: (2017)

Chimpanzee adenoviral vectors as vaccines – challenges to move the technology into the fast lane
di: Alessandra Vitelli, et al.
Pubblicazione: (2017-12-01)

Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade
di: Anna Morena D’Alise, et al.
Pubblicazione: (2019-06-01)

PHASE I TRIAL OF A HIGHLY IMMUNOGENIC T-CELL VACCINE FOR HEPATITIS C VIRUS BASED ON NOVEL ADENOVIRAL VECTORS FROM RARE SEROTYPES
di: Barnes, E, et al.
Pubblicazione: (2009)

Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class ii invariant chain.
di: Spencer, A, et al.
Pubblicazione: (2014)

Formyl Peptide Receptor 2-Dependent cPLA2 and 5-LOX Activation Requires a Functional NADPH Oxidase
di: Tiziana Pecchillo Cimmino, et al.
Pubblicazione: (2024-02-01)

Targeting HIV-1 Where It Hurts
di: Ahmed, T, et al.
Pubblicazione: (2013)

The HIVconsv Vaccines Induce Polyfunctional and Highly Proliferative T Cells that Control In Vitro HIV Replication: HIV-CORE002 Phase-I Clinical Trial
di: Ondondo, B, et al.
Pubblicazione: (2013)

IN VIVO ANTIGENIC TARGETS OF T CELLS INDUCED BY ADENOVIRAL VECTORED VACCINES IN PATIENTS WITH CHRONIC HCV INFECTION
di: Kelly, C, et al.
Pubblicazione: (2012)

Entanglement entropy in conformal quantum mechanics
di: Michele Arzano, et al.
Pubblicazione: (2023-10-01)

Innovating through Clusters
di: Chiara D'Alise, et al.
Pubblicazione: (2014-11-01)

SoCIAL – training cognition in schizophrenia: a pilot study
di: Palumbo D, et al.
Pubblicazione: (2017-07-01)